ONKURE THERAPEUTICS, INC. Research and Development Expense
ONKURE THERAPEUTICS, INC. (OKUR) reported Research and Development Expense of $12.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- ONKURE THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $12.61M, a 0.02% decline year-over-year.
- ONKURE THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $11.71M, a 10.03% decline year-over-year.
- ONKURE THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $10.72M, a 25.35% decline year-over-year.
- ONKURE THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $11.91M, a 17.78% increase year-over-year.
- ONKURE THERAPEUTICS, INC. research and development expense for fiscal 2025 was $48.26M, a 10.20% increase from fiscal 2024.
- ONKURE THERAPEUTICS, INC. research and development expense for fiscal 2024 was $43.80M, a 36.37% increase from fiscal 2023.
- ONKURE THERAPEUTICS, INC. research and development expense for fiscal 2023 was $32.12M, a 14.83% decline from fiscal 2022.
- ONKURE THERAPEUTICS, INC. research and development expense for fiscal 2022 was $37.70M, a 33.85% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $12.61M 10-Q · filed 2026-08-04 | $24.32M 10-Q · filed 2026-08-04 | $35.04M derived: sum of 3 quarters · filed 2026-08-04 | $46.95M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $11.71M 10-Q · filed 2026-05-05 | $22.43M derived: sum of 2 quarters · filed 2026-05-05 | $34.34M derived: sum of 3 quarters · filed 2026-05-05 | $46.95M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $10.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $22.64M derived: sum of 2 quarters · filed 2026-03-12 | $35.25M derived: sum of 3 quarters · filed 2026-08-04 | $48.26M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $11.91M 10-Q · filed 2025-11-06 | $24.53M derived: sum of 2 quarters · filed 2026-08-04 | $37.54M 10-Q · filed 2025-11-06 | $51.90M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $12.61M 10-Q · filed 2026-08-04 | $25.63M 10-Q · filed 2026-08-04 | $39.99M derived: sum of 3 quarters · filed 2026-08-04 | $50.10M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $13.01M 10-Q · filed 2026-05-05 | $27.37M derived: sum of 2 quarters · filed 2026-05-05 | $37.49M derived: sum of 3 quarters · filed 2026-05-05 | $48.24M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $14.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $24.48M derived: sum of 2 quarters · filed 2026-03-12 | $35.23M derived: sum of 3 quarters · filed 2026-03-12 | $43.80M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $10.12M 10-Q · filed 2025-11-06 | $904.00K 10-Q · filed 2024-11-07 | $20.87M derived: sum of 2 quarters · filed 2025-11-06 | $29.43M 10-Q · filed 2025-11-06 | $6.44M 10-Q · filed 2024-11-07 | $22.54M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $10.75M 10-Q · filed 2025-08-12 | $590.00K 10-Q · filed 2024-08-13 | $19.32M 10-Q · filed 2025-08-12 | $5.53M 10-Q · filed 2024-08-13 | $12.42M derived: sum of 3 quarters · filed 2025-08-12 | $26.05M derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | $8.57M 10-Q · filed 2025-05-06 | $4.94M 10-Q · filed 2024-05-07 | $1.67M derived: sum of 2 quarters · filed 2025-05-06 | $15.29M derived: sum of 3 quarters · filed 2025-05-06 | $29.69M derived: sum of 4 quarters · filed 2025-05-06 | |||
| 2023-12-31 | -$6.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $6.73M derived: sum of 2 quarters · filed 2025-03-10 | $21.13M derived: sum of 3 quarters · filed 2025-03-10 | $32.12M 10-K · filed 2025-03-10 | $56.61M 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $13.62M 10-Q · filed 2024-11-07 | $28.02M derived: sum of 2 quarters · filed 2024-11-07 | $39.01M 10-Q · filed 2024-11-07 | $49.37M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $14.40M 10-Q · filed 2024-08-13 | $25.39M 10-Q · filed 2024-08-13 | $35.75M derived: sum of 3 quarters · filed 2024-08-13 | $45.69M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $10.99M 10-Q · filed 2024-05-07 | $21.35M derived: sum of 2 quarters · filed 2024-05-07 | $31.29M derived: sum of 3 quarters · filed 2024-05-07 | $39.42M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | $10.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $20.30M derived: sum of 2 quarters · filed 2024-03-28 | $28.43M derived: sum of 3 quarters · filed 2024-03-28 | $37.70M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $9.94M 10-Q · filed 2023-11-13 | $18.07M derived: sum of 2 quarters · filed 2023-11-13 | $27.35M 10-Q · filed 2023-11-13 | $34.45M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $8.13M 10-Q · filed 2023-08-10 | $17.41M 10-Q · filed 2023-08-10 | $24.51M derived: sum of 3 quarters · filed 2023-08-10 | $33.83M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $9.28M 10-Q · filed 2023-05-11 | $16.38M derived: sum of 2 quarters · filed 2023-05-11 | $25.70M derived: sum of 3 quarters · filed 2023-05-11 | $31.98M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $7.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $16.42M derived: sum of 2 quarters · filed 2023-03-27 | $22.70M derived: sum of 3 quarters · filed 2023-03-27 | $28.17M 10-K · filed 2023-03-27 | ||||
| 2021-09-30 | $9.32M 10-Q · filed 2022-11-08 | $15.60M derived: sum of 2 quarters · filed 2022-11-08 | $21.07M 10-Q · filed 2022-11-08 | $26.19M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $6.28M 10-Q · filed 2022-08-09 | $11.75M 10-Q · filed 2022-08-09 | $16.87M derived: sum of 3 quarters · filed 2022-08-09 | $21.30M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $5.47M 10-Q · filed 2022-05-10 | $10.59M derived: sum of 2 quarters · filed 2022-05-10 | $15.02M derived: sum of 3 quarters · filed 2022-05-10 | $17.84M derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | $5.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $9.55M derived: sum of 2 quarters · filed 2022-03-23 | $12.37M derived: sum of 3 quarters · filed 2022-03-23 | $15.94M 10-K · filed 2022-03-23 | ||||
| 2020-09-30 | $4.43M 10-Q · filed 2021-11-12 | $7.25M derived: sum of 2 quarters · filed 2021-11-12 | $10.83M 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | $2.82M 10-Q · filed 2021-08-11 | $6.39M 10-Q · filed 2021-08-11 | ||||||
| 2020-03-31 | $3.58M 10-Q · filed 2021-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |